CDEX TECH DIRECTOR RECIEVES: the Williams-Wright Award

The Coblentz Society



http://www.coblentz.org/awards/the-williams-wright-award

CDEX's Tech Director John Coates

http://www.infoscience.com/JPAC/ManScDB/JPACDBEntries/1394038429.pdf

2014 Miniaturized solid state spectrometers

Chemical identification…materials in unlabeled containers


New Technologies Simple Photometric Engines
& Applications
? UV-Visible Light Photometric Sensors
? Color-based measurements
? Fluorescence methods
? Near-Infrared Photometric Sensors
? Solvents, oil and petroleum products
? Reaction monitoring – known targets
? Liquid products – consumer products
? Powders and solid substrates
? Mid-Infrared Photometric Sensors
? Mid-IR Photometer…includes handheld diagnostic systems
? Multicomponent gas analyzers
? Multicomponent fluid analyzers

http://online.wsj.com/article/PR-CO-20140818-904339.html
ugust 18, 2014, 8:35 a.m. ET

CDEX Expands Technical Development Team With Appointment of John Coates, Ph.D. as Technical Director for Spectroscopy Products

The KEY WORDS are FOUR YEARS AGO! Cdex is still here!

So RYLES joined MP? I thought he didn't like MP? I don't know about Firmbach. If there was no money to be had! Then why did they do it? Didn't they have a fair idea that they could sink the Cdex?

Was RYLES one of the three?

Now one must report it correct, THREE out of SEVENTEEN said no.

Three ex CDEX employees who knew for a fact, the Cdex had no cash funds to pay the 17 note holders. So why would 3 demand something they KNEW could not be given? Really, just how obvious is that answer.

The other 14 note holders wanted Cdex to continue to move forward, which is EXACTLY why they ALL said yes. But the 3 ex Cdex employee's wanted Cdex to end.

Anticipating trouble is what "great" leadership does. When a CEO, President, or other like leader, does not ask the right questions before potential trouble rears its head, he/she is not much of a leader.

That type of forward thinking needs no explanation either.

Once again, the SEC filings tell the facts. The BK was NOT Mr. Brumfield's choice. There was NO CASH FUNDS in Cdex Inc to pay the 17 note holders.

Here was the note to restructure: CDEX Chairman and CEO Jeff Brumfield said the company was forced to file for bankruptcy reorganization after failing to win the approval of creditors on about $2.5 million in unsecured debt remaining on a $4.5 million note. Last June, the company announced that its debenture holders converted about $1.9 million worth of notes to 22.2 million shares.

History is very clear, Cdex Inc did not have 2.5 million cash to pay out. It was imperative that the note holders agree to restructure, or Cdex was going into BK.

Mr. Brumfield DID NOT wait to the day before, or the week before, or the month before such note was due, to start trying to restructure the note. He started a couple months before this note was due, working with the note holders. His understanding of the importance to restructure a note, that could bankrupt Cdex, if not restructured, speaks volumes as to his leadership qualities. He sought guidance months ahead, so he would clearly understand the Cdex options, in the event that the note holders would not restructure.

Three ex employees refused to accept terms, that the other 14 had, so that Cdex would not be forced into BK.

Cdex did NOT have millions of dollars to pay to note holders. The note holders had to agree to restructure, 14 said yes and 3 said no. It was very clear to the three who said no, what would happen to Cdex. They could have cared less.

NEWS: CDEX Inc. to Present at the National Investment Banking Association's 132nd Investment Conference
Marketwired
August 25, 2014: 08:30 AM ET

CDEX Inc. (OTCQB: CDEX), a pioneering developer, manufacturer and distributor of patented, real-time chemical detection and validation technologies for the healthcare and security markets, today announced that the Company has been invited to present at the National Investment Banking Association's ("NIBA") 132nd Investment Conference to be held in New York on September 15-17, 2014.

NIBA is a national not-for-profit trade association of regional and independent brokerages, investment banking firms, institutional investors and related capital market service providers. Since its inception, NIBA member firms have successfully completed over 1000 equity offerings totaling approximately $10 billion in new capital for America's finest emerging growth companies. The member firms of NIBA represent over 8800 registered representatives with an estimated $78 billion in assets under management, and are responsible for 90% of all Initial Public Offerings under $20 million.

NIBA conferences provide a venue for invited companies to share meaningful insight into their business operations, short and long-term growth strategies and industry vision, give its members the opportunity to exchange ideas and information, evaluate presentations made by public and private companies seeking capital or exposure to the investor community.

EVENT AT A GLANCE

WHO: Jeffrey Brumfield - Chairman and Chief Executive Officer Jason Terrell, M.D. - Medical Director John Coates, Ph.D. - Technical Director of Spectroscopy Products

WHEN: September 15-17, 2014

WHERE: The Roosevelt Hotel 45 E. 45th Street

About CDEX Inc.

Headquartered in Tucson, Arizona, CDEX is engaged in pioneering technological advancements in the field of chemical and medication detection and validation for the healthcare and security markets. The Company's proprietary solutions are based on its patented Enhanced Photoemission Spectroscopy technology for substance verification, authentication and identification; and include the ValiMed™ Medication Validation System product line marketed to healthcare markets worldwide for use in combatting diversion of controlled substances and narcotics, as well as compounded liquid pharmaceuticals to help ensure patient safety, and the ID2™ product line marketed to the global security market for use in detecting illegal or illicit drugs in difficult-to-monitor, critical environments. For more information, please visit www.cdex-inc.com.

Is Dr. Coates a great fit for CDEX or WHAT? His highly cited work includes some scenarios very much like we've been reading about right here (I think)

This one is cited in papers over and over again. I think I saw that over 1,100 citations are out there

http://www.spectroscopynow.com/userfiles/sepspec/file/specNOW/eac10815.pdf


Interpretation of Infrared Spectra, A Practical Approach

John Coates

in

Encyclopedia of Analytical Chemistry


Note that sometimes there are several options in the

way that a sample may be handled for infrared analysis.

It is often beneficial to consider the different options.

Before we start to examine the situation it is important to

understand the importance of the interpretation and to

determine the real requirements. Here are some example

scenarios:

1. The sample (or spectrum) is a ‘‘total unknown’’

and an identification is required – examples include

forensic samples, environmental waste samples, or

new discovery samples, where a new material has

been synthesized or discovered.

2. The sample (or spectrum) is an unknown and it

needs to be characterized or classified – examples

include commercial applications where new additives

or components are included in a material to provide

a specific property; in such cases this could be

considered the basis of competitive product analysis.

3. The sample generally is known but the existence of

a specific chemical class needs to be determined –

examples include contaminant analysis, analysis

for toxicology or environmental reasons, material

additives, etc.

4. The sample is a complete known and the interpretation

is required to confirm the material composition

and/or quality – examples include product

quality control and the confirmation of a structure

or functionality of a newly synthesized material

There are clearly many other scenarios that can be

considered, and the examples presented may cross over

into more than one of these scenarios. However, the idea

here is to help define a strategy for the interpretation.

I wonder what Mr. Ryles is doing these days?

Jim Ryles? Does anybody have anymore information on Jim Ryles? Sounds like he wasn't producing a darn thing for Cdex! Drawing a paycheck and doing nothing!


"Good ole Jim Ryles was collecting a paycheck while watching TV in the back at his days at CDEX! One must wonder what checks he is collecting nowadays !!!!!! Go CDEX!! JR"

Cool !! I thought I saw stuff about Pittcon here before. They say their audience is not just “analytical chemists,” but all laboratory scientists—anyone who identifies, quantifies, analyzes or tests the chemical or biological properties of compounds or molecules, or who manages these laboratory scientists.

WILLIAMS WRIGHT AWARDTHE COBLENTZ SOCIETY. John Coates, Coates Consulting LLC, will receive the 2013 Williams Wright Award from the CoblentzSociety. John Coates was educated in the UnitedKingdom; Grad RSCand PhD from Brunel University. He started work as an analytical chemist in 1964 with Castrol Oil (UK). In 1974, he joined Perkin-Elmer (UK), moving to the corporate office (USA) in 1978. From 1984 Dr, Coates held positions with other major instrument companies. In 1996 he formed Coates Consulting LLC, a company focused on instrument and sensor development.

http://pittcon.org/wp-content/uploads/2013/03/Applied-Spectroscopy-Pittcon-2013.pdf

http://pittcon.org/about-pittcon/

Pittcon is the world’s largest annual premier conference and exposition on laboratory science. It is organized by The Pittsburgh Conference on Analytical Chemistry and Applied Spectroscopy, a Pennsylvania not-for-profit educational corporation which is comprised of the Spectroscopy Society of Pittsburgh (SSP) and the Society for Analytical Chemists of Pittsburgh (SACP).

Pittcon attracts more than 18,000 attendees from industry, academia and government from 90 countries worldwide and is managed by a committee of volunteers and a 11-person staff. Proceeds from Pittcon fund science education and outreach at all levels, kindergarten through adult.

Pittcon’s target audience is not just “analytical chemists,” but all laboratory scientists—anyone who identifies, quantifies, analyzes or tests the chemical or biological properties of compounds or molecules, or who manages these laboratory scientists.

The Analytical and statistical Evaluation of Infrared Spectroscopic Data from Used Diesel Lubricants


Technical Paper

1984-10-01

John P. Coates, Lynn C. Setti, Burwell B. McCaa

Infrared spectroscopy is one of the most important analytical tools for the study of lubricant degradation and for condition monitoring of oils during service. The application of computer post processing to an infrared spectrum provides a means for the extraction of oil degradation data from a used diesel oil sample without need for the separation of soot and other dispersed insoluble material. Data acquired by this type of approach are representative of the actual condition of the lubricant and they provide a basis for monitoring oil degradation insitu. This paper will discuss physical and chemical characteristics pertinent to the performance and condition of used diesel oils that are reflected in the infrared spectrum. It will also provide a summary of the results from a statistical study of infrared data accumulated from oils taken from five different types of diesel engine in current service with military equipment.

American Pharmaceutical Review is the leading review journal for business and technology in the pharmaceutical industry throughout North America.



http://www.americanpharmaceuticalreview.com/1501-About-Us/

Cdex's: N.I.H., U.S. Library of Medicine: John P. Coates and Stephen A. Reber - The Perkin-Elmer approach to computer-aided chemistry: an overview of the technological trends in laboratory computing

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2547573/

J Automat Chem. 1984; 6(2): 67–73.

doi: 10.1155/S1463924684000146

PMCID: PMC2547573

The Perkin-Elmer approach to computer-aided chemistry: an overview of the technological trends in laboratory computing

Stephen A. Reber and John P. Coates

http://www.perkinelmer.com/OurCompany/AboutUs/default.xhtml


PerkinElmer - Making a Difference Every Day

Backed by an outstanding team of 7,600 employees and located in over 150 countries across the world, PerkinElmer is a global leader focused on improving human and environmental health, for the better. We provide our customers with critical knowledge, expertise and innovative detection, imaging, software, and services solutions so that they can make better decisions for better outcomes. At PerkinElmer, we make a difference everyday – helping scientists, clinicians and governments detect earlier and more accurately to improve the health and safety of people and the environment. Our solutions range from enabling the discovery of more effective diagnostics and therapies, to making sure that the food we eat, the water we drink, and our environment are safe from contaminants.

Discover how, together with our customers, we are making a positive impact across the world:
•For more effective drugs…PerkinElmer technologies and expertise were instrumental in the development of 26 novel therapeutic drugs
•For healthier babies… Our neonatal and newborn screening technologies have aided in screening 450 million babies worldwide for a variety of life-threatening diseases, helping to get off to a healthier start
•For better treatment…We touch over one million lives every year through cancer treatment with our advances in digital imaging technology
•For a cleaner and safer environment… Our instrumentation and solutions help to detect and analyze approximately 2.25 billion air, water, and soil samples to support ensuring safety standards and detecting environmental threats
•For more informed scientific decisions… Serving over two million scientists worldwide with our electronic laboratory notebook and software

Yesterdays PR: CDEX Expands Technical Development Team With Appointment of John Coates, Ph.D. as Technical Director for Spectroscopy Products

Last update: 18/08/2014 8:30:00 am


CDEX Expands Technical Development Team With Appointment of John Coates, Ph.D. as Technical Director for Spectroscopy Products

TUCSON, AZ--(Marketwired - Aug 18, 2014) - CDEX Inc. (OTCQB: CDEX), a pioneering developer, manufacturer and distributor of patented, real-time chemical detection and validation technologies for the healthcare and security markets, today announced the expansion of its technical development team with the appointment of John Coates, Ph.D. as Technical Director for Spectroscopy Products.

A globally recognized spectroscopist and instrumentation expert with 40-years' experience in the fields of applied spectroscopy and analytical method development, Dr. Coates is charged with guiding the ongoing development of CDEX's spectral management systems for medication analysis and validation, with specific focus on achieving optimal performance of the ValiMed(TM) Medical Validation System product line. ValiMed solutions rely on a unique combination of specialized spectroscopic measurement techniques -- including Raman, UV absorption and molecular fluorescence -- to accurately analyze, identify and determine the concentration of a drug/dose within seconds.

Commenting on Dr. Coates' appointment, Dr. Wade Poteet, Chief Scientist at CDEX, noted, "We feel very privileged to have John joining our development team and fully expect that he will play an invaluable role in helping CDEX to further enhance the powerful capabilities of our current and future generations of ValiMed devices, particularly as we persist in our efforts to identify and develop several new market applications of our patented technologies."

Over the past four decades, Dr. Coates has earned global distinction for his many accomplishments in spectroscopic measurements and instrumentation. In 2013, the industry coveted Williams-Wright Award was bestowed on him by the Coblentz Society honoring his extraordinary body of work in the field. From 1974 through 1996, Dr. Coates served several leading industrial instrument manufacturers; and in 1996, he formed Coates Consulting, LLC, a firm specializing in scientific and industrial instrumentation. Since that time, he has advised client companies on the design and development of more than 75 unique instrument systems.

Dr. Coates graduated from Royal Windsor Grammar School for Boys, Windsor, Berkshire, England in 1964. He opted not to go directly to university in favor of beginning a career in Analytical Chemistry, working in the Castrol Lubricants Research Laboratories in Bracknell, Berkshire. Dr. Coates obtained his undergraduate degree as a GradRIC (Graduate of the Royal Institute of Chemistry, now the Royal Society of Chemistry) in 1971 while continuing to work as an Analytical Methods Development Chemist at Castrol (then Burmah-Castrol). Additional specializations included Industrial Administration (Business and Management) and Graphic/Classical Art (1969-1972). He began pursuing his Ph.D. in Analytical Chemistry in 1972 at Brunel University, West London, England. He started his thesis while working at Burmah-Castrol, Bracknell and also at the Burmah Research Laboratories, Bromborough, Cheshire. His thesis topic was the Analytical Chemistry of Synthetic Gas Turbine Engine Oils as applied to high performance jet engines (Olympus engines used in the Concorde Jet Airliner). Dr. Coates earned his Ph.D. 16 years later while working at Nicolet Instrument Corporation in the United States. His professionally awarded degrees and qualifications include Chartered Chemist (CChem) (similar to a certified professional), Chartered Scientist (CSci) and Fellow of the Royal Society of Chemistry (FRSC).

About CDEX Inc.

Headquartered in Tucson, Arizona, CDEX is engaged in pioneering technological advancements in the field of chemical and medication detection and validation for the healthcare and security markets. The Company's proprietary solutions are based on its patented Enhanced Photoemission Spectroscopy technology for substance verification, authentication and identification; and include the ValiMed(TM) Medication Validation System product line marketed to healthcare markets worldwide for use in combatting diversion of controlled substances and narcotics, as well as compounded liquid pharmaceuticals to help ensure patient safety, and the ID2(TM) product line marketed to the global security market for use in detecting illegal or illicit drugs in difficult-to-monitor, critical environments. For more information, please visit www.cdex-inc.com.

Forward-Looking Statements

This news release may contain forward-looking statements. Forward-looking statements are indicated by words such as "expects," "intends," "anticipates," "believes," "forecasts," "plans" and similar expressions. These forward looking statements are based on our current expectations and actual results could differ materially. Our ability to achieve the results anticipated in such forward-looking statements is subject to risks and uncertainties, including, without limitation, our ability to successfully centralize and consolidate various support functions, operating results, market acceptance of our solutions, strong brand recognition and other risks detailed from time to time in our reports filed with the Securities and Exchange Commission. These forward-looking statements are made in accordance with "safe harbor" provided by the Private Securities Litigation Reform Act of 1995 and no assurance can be given that the future results that are the subject of such forward-looking statements will be achieved. The Company undertakes no obligation to publicly update or revise the forward-looking statements, whether as a result of new information, future events, or otherwise.

For More Information, Please Contact:

Hanover|Elite

Kathy Addison

COO

407-585-1080

Email Contact

(MORE TO FOLLOW) Dow Jones Newswires

August 18, 2014 08:30 ET (12:30 GMT)

Cdex's: John P. Coates Expert - Witnesses & Forensic Consultant, Chartered Scientist and Chemist an expert witness, Areas of Expertise include Chemistry & Chemical Processes; Patents, an expert witness in applied and industrial instrumentation, optical spectroscopy and analytical instruments, especially automotive sensors and environmental and industrial micro spectral measurement device matters



https://www.lexvisio.com/expert-witness/john-p-coates-coates-consulting

Dec. 2013, American Pharmaceutical Review noteworthy advances in nir instrumentation: Dr. John Coates had a huge impact in promoting smaller, faster and cheaper innovations

Identify noteworthy advances in nir instrumentation. What are the key drivers for these advancements? GR:“Faster, smaller, cheaper” is here! 1000 spectra per microseconds, 50 mm diameter or less sampling windows and under $1,000 is now a reality.The development of Diode-Array (DA),Charge Couple Device (CCD) and Linear Variable Filters (LVF) based instruments has led to smaller devices.Together with smaller computing technology that makes it possible to carry portable devices in a pocket (say, 2 x 4 x 8 inches),in conjunction with optical fibers to interface with all kinds of sample holders for the measurement,has greatly widened the range of conditions under which spectra and analyses can be obtained competitively (i.e. instrument performance gauged to regulatory-based qualification criteria).Technologies have evolved based on business needs (i.e. the morphing of fiber optic industries into spectrometer vendors), individuals have devoted their lives to pursuing the idea of miniature devices (Prof. Fred McClure and Dr. John Coates to name two who have had a huge impact in promoting smaller, faster and cheaper innovations), and a need to measure the sample in situ rather than bringing the sample to the instrument has been emphasized in the manufacturing, commerce and health sectors. All of these factors have converged to create the perfect storm, forcing the miniaturization of NIR instrumentation. The development of portable NIR instruments seems to have become a self-fulfilling prophecy – i.e. NIR as a rapid, non-destructive, non-invasive technique is now portable – based on the following basic factors: it has been done, there are men and woman who have pursued this innovation towards miniaturization, and there is now a real need to make NIR measurements for real time process quality control for medical diagnostics and to combat counterfeiting.

http://www.americanpharmaceuticalreview.com/Featured-Articles/151948-Spectroscopic-Techniques-and-PAT-Roundtable/



Commenting on Dr. Coates' appointment, Dr. Wade Poteet, Chief Scientist at CDEX, noted, "We feel very privileged to have John joining our development team and fully expect that he will play an invaluable role in helping CDEX to further enhance the powerful capabilities of our current and future generations of ValiMed devices, particularly as we persist in our efforts to identify and develop several new market applications of our patented technologies."



http://money.cnn.com/news/newsfeeds/articles/marketwire/1138220.htm



http://online.wsj.com/article/PR-CO-20140818-904339.html

Thanks HighStakes for keeping us updated on the rising stock price!

CDEX's newest doctor is a successful inventor juz google' it !! wooo whoooo!



https://www.google.com/patents/US7907282?dq=ininventor:%22John+Coates%22&hl=en&sa=X&ei=UCnyU4nLEJH9yQS0tICQBg&ved=0CLYDEOgBMDo

Integrated sensing module for handheld spectral measurements



https://www.google.com/patents/WO2011156818A3?cl=en&dq=ininventor:%22John+Coates%22&hl=en&sa=X&ei=UCnyU4nLEJH9yQS0tICQBg&ved=0CB4Q6AEwAA


Qcl spectroscopy system and applications thereforWO 2011156818 A3AbstractA spectroscopy system comprising at least two laser modules, each of the laser modules including a laser cavity, a quantum cascade gain chip for amplifying light within the laser cavity, and a tuning element for controlling a wavelength of light generated by the modules. Combining optics are used to combine the light generated by the at least two laser modules into a single beam and a sample detector detects the single beam returning from a sample.

American PHARMACEUTICAL Review June 2014 BY CDEX's JOHN COATES: A Review of New Small-Scale Technologies for Near Infrared Measurements



http://www.americanpharmaceuticalreview.com/1429-AuthorProfile/4190-John-Coates/



http://www.americanpharmaceuticalreview.com/Featured-Articles/163573-A-Review-of-New-Small-Scale-Technologies-for-Near-Infrared-Measurements/



June 18, 2014 In recent years there has been an emphasis on changing the way we view instrumentation and a desire to make instruments smaller and lower in cost [1-3].This trend was motivated by the rapid growth in telecommunication technology in the late1990s.During the past two to three years, a new set of miniaturized (small scale) instrument platforms and products have been produced, including Raman, Infrared (IR and NIR), UV/Vis, and non-optical technologies like Mass Spectrometry and NMR.However, this article focuses on new technologies applied to the near infrared (NIR).Introduction: Moving Away from Traditional Thinking, For the purpose of this article, near infrared is defined as the wavelength range from 750nm to 2600nm; from the edge of the visible to the edge of the mid-IR.Traditional process and laboratory spectrometers tend to be large and expensive.There is an active movement toward smaller systems, and a trend to make the measurement at the physical location of the “sample,” whether it is in production, a manufacturing process, or within the environment.Narrow band-pass filters,covering wavelengths from the deep-UV (220nm) to the mid-IR (15microns, 15,000nm), can be used individually or in specially combined assemblies to provide the required spectral range(s).Note that filters may be diced (cut and reduced in size) and mounted directly on or just above a detector to produce a spectrally selective detector. These may include multi-element patterned filters produced by microlithography techniques, and linear variable filters (LVF), or continuously variable filters on a single substrate. Of these, LVFs are the most versatile, and these can be configured to cover wavelength ranges from the long UV (350nm) to the mid-IR (15microns, 15,000nm).Lasers and LEDs are a natural fit, size-wise, as efficient sources for microspectrometer systems.A wide range of tunable laser diodes (TDLs) are now available, primarily in the near-infrared spectral region, and broadly tunable mid-infrared lasers are available in the form of quantum cascade lasers (QCLs).In the broadly tunable format, these lasers essentially function as a spectrometer,where tuning ranges can be as broad as 2-3 microns wide.New Technologies: Spectral Engines and Miniature SpectrometersIn combination, the enabling technologies defined above form a toolbox which is the basis of the latest generation of spectral engines and miniature spectrometersThe selection of a detector array, whether a photo-detector or thermal detector, is based on a number of key parameters, of which spectral range, sensitivity/performance, size, and cost are among the most important.Figure1The fully integrated micro NIR Spectrometer engine (A/B) featuring LvF technology combined with a inGaAs detector array (C) generating a spectral output (d).Figure 4. DLP prototype module (A) shown with variable data/spectral resolution (B) function and capability to switch from liquid (C) to solid (d) samples. American Pharmaceutical Review Summary This article has reviewed new technologies that can be applied and integrated for the measurement of optical spectra, primarily in the near infrared spectral regions



Boyo boy CDEX seems to have another jewel with Dr. Coates and just look at these references where Dr. Coates works with stuff that fits with what cdex is doing!


References
1.Coates, J.P., A review of Current and New Technology Used in Instrumentation for Industrial Vibrational Spectroscopy, Spectroscopy, 14, (10), pp. 20-34, 1999.
2.Coates, J.P., New Micro Spectrometers: Building on the Principle that Simple is Beautiful, Spectroscopy, 15, (12), 2000.
3.Coates, J.P., Spectrometric and Photometric Detectors: Opening the Doors to Miniaturized Spectroscopy, Lab International, September 2008, pp 25-27.
4.Ritchie, G. et al., American Pharmaceutical Review, Spectroscopic Techniques and PAT Roundtable, December 2013.

Author Biography

Dr. John Coates was

Milestones in Spectroscopy:

http://www.spectroscopyonline.com/spectroscopy/article/articleDetail.jsp?id=676256&sk=&date=&pageID=2

By John Coates: The vibrational spectrum of a molecule is considered to be a unique physical property and is characteristic of the molecule. As such, the infrared spectrum can be used as a fingerprint for identification by the comparison of the spectrum from an “unknown” with previously recorded reference spectra. This is the basis of computer-based spectral searching. In the absence of a suitable reference database, it is possible to effect a basic interpretation of the spectrum from first principles, leading to characterization, and possibly even identification of an unknown sample. This first principles approach is based on the fact that structural features of the molecule, whether they are the backbone of the molecule or the functional groups attached to the molecule, produce characteristic and reproducible absorptions in the spectrum. This information can indicate whether there is backbone to the structure and, if so, whether the backbone consists of linear or branched chains. Next it is possible to determine if there is unsaturation and/or aromatic rings in the structure. Finally, it is possible to deduce whether specific functional groups are present. If detected, one is also able to determine local orientation of the group and its local environment and/or location in the structure. The origins of the sample, its prehistory, and the manner in which the sample is handled all have impact on the final result. Basic rules of interpretation exist and, if followed, a simple, first-pass interpretation leading to material characterization is possible. This article addresses these issues in a simple, logical fashion. Practical examples are included to help guide the reader through the basic concepts of infrared spectral interpretation.

I am a potential CDEX shareholder. How may I receive an investor kit?

You may contact Hanover|Elite at 407-585-1080 or via email at CDEX@hanoverelite.com and they would be happy to accommodate your request for information, address any questions you may have, and/or add you to the Company’s email database to ensure you receive ongoing information about CDEX as soon as it becomes publicly available.


http://cdex-inc.com/our-company/faq/

CDEX's Sales Director John McConnell is also a founder of ATP Applied Technology Partners, and a member of Tennessee Association of Chiefs of Police.

The phone number is the same for all too.

John McConnell, CDEX Dir of Outside Sales, Security Div

http://cdex-inc.com/investors/management-team/

CDEX Announces Shipment of Ten ID2 Meth Scanners ...

finance.yahoo.com/.../CDEX-Announces-Shipment-of-i...

Jul 7, 2011 - The ID2™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to ... John McConnell (615) 218-7993

Applied Technology Partners ATP (John McConnell, same phone number)

http://atpcorporate.com/about-us.html



Tennessee Assoc of Chiefs of Police (member John McConnell, same phone number)

http://www.tacp.org/Business_Members

CDEX Patent on Biospace News:

http://www.biospace.com/News/cdex-inc-granted-notice-of-allowance-for-u-s/341683

In case you hadn't seen it....


http://cdex-inc.com/investors/ceo-corner/


Jeff Brumfield, CEO of CDEX Inc.

CDEX AT-A-GLANCE

A brief overview of our Company. COMING SOON.

CDEX Webpage Up-Dated

http://cdex-inc.com/investors/investor-relations/

Investor Relations

Home » Investors » Investor Relations
Welcome to our Investor Information Center

On behalf of CDEX Inc., I welcome you to our Company’s online Investor Information Center. Here we provide a broad range of material that we believe is essential in helping you learn about us and our key growth strategies and progress toward our goals. These materials include:
•Our corporate goals, strategy and information about our business operations;
•Financial reports and details related to our common stock;
•Biographies of our leadership team; and
•Press releases and media coverage.

At CDEX, we firmly believe that good corporate governance goes a long way toward building and maintaining public trust. Our employees are guided by our values to be safe, maintain the highest integrity, treat everyone with dignity and respect, focus on our customers and demonstrate excellence in all we do. We believe this will lead to sustainable economic success and enduring shareholder value. Our policies and practices have been crafted to ensure that these values are continuously upheld at all levels of our Company.

Our Investor Information Center is designed to keep you informed of material developments at our Company and to provide transparency into our business operations. We are committed to providing excellent service to our shareholders and to the global investment community. To that end, we encourage you to share your questions and comments with us. If you require information that is not already posted on our site, please let us know. You can reach our investor relations counsel at CDEX@hanoverelite.com or by way of our Contact Us page.

Thank you very much for your interest in CDEX and for your ongoing support.

Sincerely,
CDEX INC.

Jeff Brumfield

Chairman and Chief Executive Officer

Investor Relations
•Hanover|Elite
•222 S. Magnolia Ave.
•Sanford, FL 32771
•Phone: 407-585-1080
•Email: CDEX@hanoverelite.com

More than just another vendor, Elite strives to be a valued team member and strategic partner for our clients. Elite's talented team of take-charge professionals works tirelessly to deliver consistent, quantifiable results that are supported by tangible evidence in the market.

At Elite, we understand the intricacies of the capital markets, the investment process and the psychology at work in the various sectors of the investing universe. Consequently, we are well-equipped to assist our clients in achieving both short and long term corporate and market objectives - irrespective of perceived hurdles.""

And this one:


Elite combines diverse business expertise, influence, talent and capabilities to achieve quantifiable results for those publicly traded and privately held companies the firm proudly represents. Elite works closely with its clients’ executive leadership teams to develop and implement customized, fully integrated marketing and communications strategies and programs designed to achieve transparency and proactive communications with shareholders, as well as foster and enhance broad investor and media interest. Elite understands the intricacies of the capital markets, the investment process and the psychology at work in the various sectors of the investing universe. Consequently, the firm is well equipped to assist its clients in achieving both short and long term corporate and market objectives - irrespective of perceived hurdles.

Specialties
Investor Relations, Public Relations, Media Relations, Social Media, Public Companies, Private Equity, Sarbanes-Oxley, Financial Conference, Debt Finance, Private Placement , IPO, secondary offering, Strategic marketing, communications consulting, brand building, reputation management, government relations, crisis management, professional copywriting


This is on Hanover Elites web sites. This company is the real deal.

Here is a link to the Cdex website:

http://cdex-inc.com/

Hanover Elite Press Release July 22, 2014 Working in concert with Hanover|Elite, we are developing, implementing and supporting a fully integrated investor and public relations strategy designed to elevate our Company's profile on both Wall Street and Main Street and, in the process, attract a much broader audience of prospective new Apptigo stakeholders.

Investor and Public Relations Activities
"On the corporate communications front, Apptigo has recently engaged the firm of Hanover|Elite, a full service financial communications company specializing in investor relations, corporate branding, regulatory compliance and capital markets access and advisory. Working in concert with Hanover|Elite, we are developing, implementing and supporting a fully integrated investor and public relations strategy designed to elevate our Company's profile on both Wall Street and Main Street and, in the process, attract a much broader audience of prospective new Apptigo stakeholders.

"In addition, it is our goal to be in position to up-list our common stock to a national trading exchange within the next 12 months. To that end, our management team intends to begin meeting with officials from both the Nasdaq OMX and New York Stock Exchange later this year to begin our preparation for an uplisting. We will also be conducting non-deal financial road shows in key U.S. financial centers and plan to participate in select investment conferences and forums in the coming months -- all with a goal of winning Apptigo greater awareness among investment professionals, digital media analysts and institutional investors. As events are confirmed, we will issue press announcements containing the salient details.

"To ensure that you receive ongoing information about Apptigo as soon as it becomes publicly available, we'd like to invite you to provide us with your preferred contact information so that Hanover|Elite can ensure you are added to our appropriate email or phone database. As we release important news announcements, details about scheduled conference calls and investor meetings, and other important communique, you can count on being notified in a timely manner. It is through these types of proactive activities that we intend to reach and educate our stakeholders and the professional investment community, at large, on Apptigo's compelling growth strategies, market differentiation and long term growth potential.

http://www.marketwatch.com/story/apptigo-international-issues-formal-corporate-update-2014-07-22

CDEX Director James G. Stevenson

July 1, 2014 JG Stevenson leading the advancement of tech & automation in the pharmacy enterprise enhancing safety of medication; with Massachusetts General Hospital and ASHP



http://www.ashpfoundation.org/MainMenuCategories/CenterforPharmacyLeadership/PharmacyLeadershipAcademy/ACPE-Continuing-Education

CDEX ValiMed G4 Booth Graphics By Christine Simpson on March 27, 2014







http://gr8scottdesign.com/portfolio/booth-graphics-2

CDEX Patent Up-Graded



http://portal.uspto.gov/pair/PublicPair




Application Number:
13/673,270
Status: Notice of Allowance Mailed -- Application Received in Office of Publications

Good posts Capn'Mike, thank you for the information.

Pennstreet, I agree 100% with your posts!

Great post Penny. I often wonder why people would waste so much time (years of their lives) posting on a message board. I guess their lives are so empty, that they will do anything for attention? If Cdex fails it fails. Most people are over it years and years ago.

A Happy New Year to all.

Cdex Shareholders: Have a happy and safe Thanksgiving.

It is really great to see Cdex shareholders posting one again.

NEWS:CDEX Completes Shipment of 10 ValiMed CCT Systems Ahead of Schedule

TUCSON, AZ, Mar 25, 2013 (MARKETWIRE via COMTEX) -- CDEX Inc. (otcqb:CDEX), a leading developer of chemical detection products using patented technologies for use in healthcare, safety and security markets, today announced the company completed and shipped the 10 unit order of its ValiMed(TM) CCT drug validation system to Al-Essa Medical & Scientific Equipment Company in Safat, Kuwait ahead of schedule. The shipment completes the sale secured in December of 2012. The units will be placed in service at medical facilities throughout the region along with testing supplies for initial operation. Each unit placed requires additional service for installation and ongoing product support by CDEX for two years from the date of delivery.

"The on time completion and delivery of the 10 CCT units is a demonstration of our team's ability to execute timely. The future sales of supplies and service related to the initial transaction of these units will further our recurring sales and service revenue. The Al-Essa Group will utilize the ValiMed systems to underpin their client's efforts help assure the highest patient safety and to fight narcotics diversion in the healthcare systems they serve," stated Jeff Brumfield, chairman and chief executive officer of CDEX. "Our agreement with Al-Essa Group provides CDEX Inc. access to markets in the Middle East and could be a key foothold to build our international reach in the Middle East for our Valimed technology. We intend to showcase the Valimed G4 system to their customers once final testing is completed and the contracted units are shipped to U.S. customers during the second quarter this year."

CDEX was contracted to deliver the 10 ValiMed CCT units in the first quarter of 2013 and receive final payment balance of the order within thirty days of shipment. The company will provide the initial training and support to Al-Essa's technical staff and the Al-Essa trainers and service personnel will then take full responsibilities for installation and training for their clients once both parties are satisfied with the aptitude and proficiency.

The ValiMed(TM) Medication Validation and Narcotics Return System (Model CCT), is a lightweight, compact table top instrument that can be used in virtually any clinical environment where high-risk IV medications are compounded before being dispensed to the patient, or where narcotics are returned after being dispensed. CDEX's ValiMed drug validation technology helps healthcare providers ensure patient safety and control costs by reducing medication errors and mitigating drug diversion. The patented & patent pending detection process identifies drugs in real-time, validating medication and treatment solutions authenticity and specificity.

About Al-Essa Group For over 30 years, professionals in healthcare, analytical and various other industries have experienced Al-Essa's proven commitment to deliver total solutions to clients in both private and public institutions, in Kuwait and GCC. With a long and proven experience in introducing cutting-edge healthcare and analytical equipment from world-class manufacturers, their activities range from supplying products, supporting applications and providing maintenance for medical and analytical needs, address human resource requirements through supplemental staffing and home healthcare programs, and deliver complete solutions in facility engineering. To date, Al-Essa has executed several projects on a turnkey basis by combining local project management and project support expertise with international technology partners. For more information visit www.alessakuwait.com

About CDEX Inc. CDEX develops, manufactures and globally distributes products to the healthcare, safety and security markets. The ValiMed(TM) product line provides life-saving validation of high-risk medications and pharmacy returned narcotics. The ID2(TM) product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets in the future where its proprietary products can be launched. To learn more about CDEX please visit: www.cdex-inc.com.

When Jim Ryles was supposedly "inventing" with Malcolm Philips, was he also involved with this stuff? More and more having RYLES - MP - FIRMBACh attempt our BK is sickening, eh? Drum say judge words to Ryles & MP burned hot & may surfac soon!!

http://www.nvannualreport.com/entities-DPC-JOSHUA-2415-MANAGEMENT-SERVICES-INC.aspx